Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
Regulatory FDF Prices
NA
0
FDF
0
Weekly News Recap #Phispers
1. Esn364
1. 1629229-37-3
2. Esn364
3. Esn-364
4. Fezolinetant [usan]
5. 83vne45kxx
6. A2693
7. Chembl3608680
8. As3472693-00
9. (4-fluorophenyl)-[(8r)-8-methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-6,8-dihydro-5h-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]methanone
10. Es-256364
11. A-2693
12. As-3472693-00
13. (r)-(4-fluorophenyl)(8-methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8h)-yl)methanone
14. Methanone, ((8r)-5,6-dihydro-8-methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-1,2,4-triazolo(4,3-a)pyrazin-7(8h)-yl)(4-fluorophenyl)-
15. Fezolinetant [inn]
16. Unii-83vne45kxx
17. Fezolinetant [who-dd]
18. Schembl16114810
19. Gtpl10422
20. Esn-364esn-364
21. Dtxsid601103615
22. Ex-a6226
23. Bdbm50112244
24. Who 10205
25. Compound 3 [pmid:26191358]
26. Cs-7952
27. Ac-36697
28. Hy-19632
29. D87169
30. Q27269455
31. ((8r)-5,6-dihydro-8-methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-1,2,4-triazolo(4,3-a)pyrazin-7(8h)-yl)(4-fluorophenyl)methanone
32. (4-fluorophenyl)((8r)-5,6-dihydro-8-methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-(1,2,4)triazolo(4,3-a)pyrazin-7(8h)-yl)methanone
33. (4-fluorophenyl)((8r)-8-methyl-3-(3-methyl-1,2,4- Thiadiazol-5-yl)-5,6-dihydro-1,2,4-triazolo(4,3-a)pyrazin- 7(8h)-yl)methanone
Molecular Weight | 358.4 g/mol |
---|---|
Molecular Formula | C16H15FN6OS |
XLogP3 | 1.6 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 2 |
Exact Mass | 358.10120846 g/mol |
Monoisotopic Mass | 358.10120846 g/mol |
Topological Polar Surface Area | 105 Ų |
Heavy Atom Count | 25 |
Formal Charge | 0 |
Complexity | 505 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Details:
Veozah (fezolinetant) is a neurokinin 3 (NK3) receptor antagonist being investigated for the treatment of vasomotor symptoms in patients with breast cancer.
Lead Product(s): Fezolinetant
Therapeutic Area: Oncology Brand Name: ESN364
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 27, 2024
Lead Product(s) : Fezolinetant
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Astellas Begins Phase 3 Study of Fezolinetant for VMS in Breast Cancer Patients
Details : Veozah (fezolinetant) is a neurokinin 3 (NK3) receptor antagonist being investigated for the treatment of vasomotor symptoms in patients with breast cancer.
Product Name : ESN364
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 27, 2024
Details:
Veozah (fezolinetant) is a neurokinin 3 (NK3) receptor antagonist indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.
Lead Product(s): Fezolinetant
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: ESN364
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 03, 2024
Lead Product(s) : Fezolinetant
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Astellas Initiates Phase 3 Studies of Fezolinetant for Menopause-Related VMS in Japan
Details : Veozah (fezolinetant) is a neurokinin 3 (NK3) receptor antagonist indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.
Product Name : ESN364
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 03, 2024
Details:
Veoza (fezolinetant), an investigational oral, nonhormonal medicine in clinical development for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.
Lead Product(s): Fezolinetant
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: ESN364
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 13, 2023
Lead Product(s) : Fezolinetant
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Astellas Receives Positive CHMP Opinion for VEOZA™ (fezolinetant)
Details : Veoza (fezolinetant), an investigational oral, nonhormonal medicine in clinical development for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.
Product Name : ESN364
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 13, 2023
Details:
Veozah (fezolinetant) works by blocking NKB binding on the kisspeptin/neurokinin B/dynorphin neuron to modulate neuronal activity in the hypothalamus to reduce the frequency and severity of moderate to severe VMS due to menopause.
Lead Product(s): Fezolinetant
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: ESN364
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 12, 2023
Lead Product(s) : Fezolinetant
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Astellas' VEOZA™ (fezolinetant) Approved by European Commission for Treatment of Vasomotor Sympt...
Details : Veozah (fezolinetant) works by blocking NKB binding on the kisspeptin/neurokinin B/dynorphin neuron to modulate neuronal activity in the hypothalamus to reduce the frequency and severity of moderate to severe VMS due to menopause.
Product Name : ESN364
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 12, 2023
Details:
Veozah (fezolinetant) works by blocking NKB binding on the kisspeptin/neurokinin B/dynorphin neuron to modulate neuronal activity in the hypothalamus to reduce the frequency and severity of moderate to severe VMS due to menopause.
Lead Product(s): Fezolinetant
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: ESN364
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 28, 2023
Lead Product(s) : Fezolinetant
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Veozah (fezolinetant) works by blocking NKB binding on the kisspeptin/neurokinin B/dynorphin neuron to modulate neuronal activity in the hypothalamus to reduce the frequency and severity of moderate to severe VMS due to menopause.
Product Name : ESN364
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 28, 2023
Details:
Veozah (fezolinetant) works by blocking NKB binding on the kisspeptin/neurokinin B/dynorphin neuron to modulate neuronal activity in the hypothalamus to reduce the frequency and severity of moderate to severe VMS due to menopause.
Lead Product(s): Fezolinetant
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: ESN364
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 13, 2023
Lead Product(s) : Fezolinetant
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Astellas' VEOZAH™ (fezolinetant) Approved by U.S. FDA for Treatment of Vasomotor Symptoms Due to...
Details : Veozah (fezolinetant) works by blocking NKB binding on the kisspeptin/neurokinin B/dynorphin neuron to modulate neuronal activity in the hypothalamus to reduce the frequency and severity of moderate to severe VMS due to menopause.
Product Name : ESN364
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 13, 2023
Details:
ESN364 (fezolinetant) works by blocking NKB binding on the kisspeptin/neurokinin B/dynorphin neuron to modulate neuronal activity in the hypothalamus to reduce the frequency and severity of moderate to severe VMS due to menopause.
Lead Product(s): Fezolinetant
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: ESN364
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 20, 2023
Lead Product(s) : Fezolinetant
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Astellas Provides Update on Fezolinetant New Drug Application in U.S.
Details : ESN364 (fezolinetant) works by blocking NKB binding on the kisspeptin/neurokinin B/dynorphin neuron to modulate neuronal activity in the hypothalamus to reduce the frequency and severity of moderate to severe VMS due to menopause.
Product Name : ESN364
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 20, 2023
Details:
Fezolinetant is an investigational selective NK3 receptor antagonist and is not approved for use anywhere in the world. Safety analyses demonstrated that both endometrial hyperplasia and endometrial malignancy were within pre-specified limits for fezolinetant-treated patients.
Lead Product(s): Fezolinetant
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: ESN364
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 10, 2022
Lead Product(s) : Fezolinetant
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Fezolinetant is an investigational selective NK3 receptor antagonist and is not approved for use anywhere in the world. Safety analyses demonstrated that both endometrial hyperplasia and endometrial malignancy were within pre-specified limits for fezolin...
Product Name : ESN364
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 10, 2022
Details:
Results from the SKYLIGHT 1™ and SKYLIGHT 2™ pivotal trials characterize the efficacy and safety of ESN364 (fezolinetant) for the treatment of moderate to severe VMS associated with menopause.
Lead Product(s): Fezolinetant
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: ESN364
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 30, 2022
Lead Product(s) : Fezolinetant
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
European Medicines Agency Accepts Astellas' Marketing Authorization Application for Fezolinetant
Details : Results from the SKYLIGHT 1™ and SKYLIGHT 2™ pivotal trials characterize the efficacy and safety of ESN364 (fezolinetant) for the treatment of moderate to severe VMS associated with menopause.
Product Name : ESN364
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 30, 2022
Details:
ESN364 (fezolinetant), an investigational oral, nonhormonal compound seeking approval for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. VMS, characterized by hot flashes and/or night sweats, are common symptoms of menopause.
Lead Product(s): Fezolinetant
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: ESN364
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 18, 2022
Lead Product(s) : Fezolinetant
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
U.S. FDA Accepts Astellas' New Drug Application for Fezolinetant
Details : ESN364 (fezolinetant), an investigational oral, nonhormonal compound seeking approval for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. VMS, characterized by hot flashes and/or night sweats, are common symptoms o...
Product Name : ESN364
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 18, 2022
Global Sales Information
Market Place
Reply
21 May 2024
Reply
18 Jul 2023
Reply
17 Jun 2023
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
17
PharmaCompass offers a list of Fezolinetant API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Fezolinetant manufacturer or Fezolinetant supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Fezolinetant manufacturer or Fezolinetant supplier.
PharmaCompass also assists you with knowing the Fezolinetant API Price utilized in the formulation of products. Fezolinetant API Price is not always fixed or binding as the Fezolinetant Price is obtained through a variety of data sources. The Fezolinetant Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Fezolinetant manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Fezolinetant, including repackagers and relabelers. The FDA regulates Fezolinetant manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Fezolinetant API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Fezolinetant manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Fezolinetant supplier is an individual or a company that provides Fezolinetant active pharmaceutical ingredient (API) or Fezolinetant finished formulations upon request. The Fezolinetant suppliers may include Fezolinetant API manufacturers, exporters, distributors and traders.
click here to find a list of Fezolinetant suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Fezolinetant DMF (Drug Master File) is a document detailing the whole manufacturing process of Fezolinetant active pharmaceutical ingredient (API) in detail. Different forms of Fezolinetant DMFs exist exist since differing nations have different regulations, such as Fezolinetant USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Fezolinetant DMF submitted to regulatory agencies in the US is known as a USDMF. Fezolinetant USDMF includes data on Fezolinetant's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Fezolinetant USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Fezolinetant suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Fezolinetant as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Fezolinetant API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Fezolinetant as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Fezolinetant and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Fezolinetant NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Fezolinetant suppliers with NDC on PharmaCompass.
Fezolinetant Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Fezolinetant GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Fezolinetant GMP manufacturer or Fezolinetant GMP API supplier for your needs.
A Fezolinetant CoA (Certificate of Analysis) is a formal document that attests to Fezolinetant's compliance with Fezolinetant specifications and serves as a tool for batch-level quality control.
Fezolinetant CoA mostly includes findings from lab analyses of a specific batch. For each Fezolinetant CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Fezolinetant may be tested according to a variety of international standards, such as European Pharmacopoeia (Fezolinetant EP), Fezolinetant JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Fezolinetant USP).